

SINGULEX LAUNCHES PRESENCE IN EUROPE

*Developer of the World's First High-Definition Immunodiagnostic Technology
Announces New R&D Center, Strategic Partnerships and Product Launch*

ALAMEDA, California, September 2, 2010 -- Singulex, Inc., the leader in high-definition immunodiagnostic technology has set up its first European R&D center in France in association with the Lyon-based innovation cluster Lyonbiopôle. In addition to supporting cutting edge research in the treatment of inflammatory and cardiovascular disease, the new location will provide sales and technical support to European clients. Beginning this month in partnership with Lyon-based Indicia Biotechnology, Singulex will introduce its distinctive portfolio of immunoassay technology to the European biotech and pharmaceutical market.

“Singulex is committed to making our technology available to the European market, and we are excited about this new phase in our company’s growth,” said Singulex CEO Philippe Goix. “The selection of Lyon as our operating location was sealed by the unmatched opportunities offered by Lyonbiopôle in terms of funding potential, partnerships with academic, hospital and corporate leaders in our field, as well as the proximity to other key biotech hubs like Switzerland and the UK.”

Lyonbiopôle is a well-established innovation cluster specializing in diagnostics and biotechnology research, and several global biotech leaders are headquartered in this region, including bioMerieux, Becton Dickinson, Merial and Sanofi Pasteur. Through its association with Lyonbiopôle, Singulex has formed a strategic partnership with Indicia Biotechnology, an established provider of immunoassay technology, assay development, and sample testing services to the European pharmaceutical and medical research community. The two companies will provide CRO and assay development services utilizing Singulex’s high-definition technology to quantitatively detect biomarkers at femtogram concentrations.

The partnership was awarded a € 2.2 million grant by France’s Single Inter-Ministry Fund (FUI) to Lyonbiopôle for an R&D program headed by Indicia Biotechnology in collaboration with the Hospices Civils de Lyon, TxCell and Novartis to develop novel biomarkers for the diagnosis and monitoring of Crohn’s Disease utilizing Singulex’s innovative Erenna® Immunoassay System. The Erenna® Immunoassay System is the first to bring high definition to protein quantification at femtogram concentrations utilizing advanced single molecule detection. The FUI funding program is a very prestigious program in France that has provided financial support for over 886 projects since 2005, representing about € 4.6 billion of R&D, 15,000 researchers, and government funding of € 1.7 billion.

“The Invest in France Agency is proud to have worked with Singulex for the past two years to optimize their company’s success in France,” said Alexandre Thermet, Vice President of the Invest in France Agency, San Francisco. “With the support of Lyonbiopôle and ADERLY, the economic development agency for the Lyon area, we were able to help identify business and partnership solutions that would optimize Singulex’s goals. The growing presence in Lyon, and throughout France, of pioneering companies like Singulex is a testament to the unique range of opportunities offered by the country’s network of specialized innovation clusters like Lyonbiopôle.”

About Singulex, Inc.

Singulex, Inc. helps manage patient health risks by answering critical health questions about disease and therapeutic intervention utilizing cutting edge immunodiagnostic products. Singulex has pioneered technology that can quantitatively detect single molecules such as proteins and metabolites in complex biological samples. The technology embedded in the Erenna System extends the dynamic range of immunoassays by orders of magnitude, allowing drug developers to use biomarkers to measure drug efficacy, safety, and disease progression. The company provides advanced CLIA-laboratory patient testing as well as industry-leading sample analysis and assay development services.

<http://www.singulex.com>

About The Invest in France Agency

The Invest in France Agency (IFA) is the national agency responsible for promoting and facilitating international investment in France. It also coordinates initiatives to promote France’s economic attractiveness. The IFA network operates worldwide, with offices in France as well as in North and South America, Europe, the Middle East and Asia. The IFA works in partnership with regional economic development agencies to offer investors outstanding business opportunities and customized services. For further information, please visit www.investinfrance.org

Invest in France Agency

Contact:

Amanda Hilson

Direct: 212-757-9340 x5207

ahilson@investinfrance.org